These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 25005492)

  • 21. The risks and costs of multiple-generic substitution of topiramate.
    Duh MS; Paradis PE; Latrémouille-Viau D; Greenberg PE; Lee SP; Durkin MB; Wan GJ; Rupnow MF; LeLorier J
    Neurology; 2009 Jun; 72(24):2122-9. PubMed ID: 19528520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.
    Zachry WM; Doan QD; Clewell JD; Smith BJ
    Epilepsia; 2009 Mar; 50(3):493-500. PubMed ID: 18616554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.
    Hartung DM; Middleton L; Svoboda L; McGregor JC
    CNS Drugs; 2012 Aug; 26(8):707-16. PubMed ID: 22731934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New Zealand patients' understanding of brand substitution and opinions on copayment options for choice of medicine brand.
    Lessing C; Ashton T; Davis P
    Aust Health Rev; 2016 Jun; 40(3):345-350. PubMed ID: 26363980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How much could be saved in Chinese hospitals in procurement of anti-hypertensives and anti-diabetics?
    Sun J; Ren L; Wirtz V
    J Med Econ; 2016 Sep; 19(9):881-8. PubMed ID: 27100310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Plotkina AV; Peissig PL; Berg RL; Page D; Hansen RA
    Epilepsy Res; 2017 Sep; 135():71-78. PubMed ID: 28641219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generic substitution of antiepileptic drugs.
    Sander JW; Ryvlin P; Stefan H; Booth DR; Bauer J
    Expert Rev Neurother; 2010 Dec; 10(12):1887-98. PubMed ID: 21091318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generic substitution in the treatment of epilepsy: patient and physician perceptions.
    Berg MJ; Gross RA; Haskins LS; Zingaro WM; Tomaszewski KJ
    Epilepsy Behav; 2008 Nov; 13(4):693-9. PubMed ID: 18589000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries.
    Paradis PE; Latrémouille-Viau D; Moore Y; Mishagina N; Lafeuille MH; Lefebvre P; Gaudig M; Duh MS
    Curr Med Res Opin; 2009 Jul; 25(7):1793-805. PubMed ID: 19505202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generic products of antiepileptic drugs (AEDs): is it an issue?
    Bialer M
    Epilepsia; 2007 Oct; 48(10):1825-32. PubMed ID: 17850324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system.
    Spence MM; Nguyen LM; Hui RL; Chan J
    Pharmacotherapy; 2012 Nov; 32(11):981-7. PubMed ID: 23074134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Low prescription rates of generic lamotrigine and gabapentine].
    Mattsson P; Lindqvist T
    Lakartidningen; 2008 Feb 6-12; 105(6):385. PubMed ID: 18380362
    [No Abstract]   [Full Text] [Related]  

  • 33. Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy.
    Das S; Jiang X; Jiang W; Ting TY; Polli JE
    Epilepsy Behav; 2020 Apr; 105():106936. PubMed ID: 32092462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generic replacement of clozapine: a simple decision model from a Canadian perspective.
    Layton S; Barbeau M
    Curr Med Res Opin; 2004 Apr; 20(4):453-9. PubMed ID: 15119982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic burden associated with the use of generic antiepileptic drugs in the United States.
    Helmers SL; Paradis PE; Manjunath R; Duh MS; Lafeuille MH; Latrémouille-Viau D; Lefebvre P; Labiner DM
    Epilepsy Behav; 2010 Aug; 18(4):437-44. PubMed ID: 20580619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experience of a medicines reference-pricing model.
    Rothberg AD; Blignault J; Serfontein CB; Valodia B; Eekhout S; Pels LM
    S Afr Med J; 2004 Mar; 94(3):183-8. PubMed ID: 15098277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brand substitution or multiple switches per patient? An analysis of pharmaceutical brand substitution in Australia.
    Kalisch LM; Roughead EE; Gilbert AL
    Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):620-5. PubMed ID: 18324613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues.
    Crawford P; Feely M; Guberman A; Kramer G
    Seizure; 2006 Apr; 15(3):165-76. PubMed ID: 16504545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between switching antiepileptic drug products and healthcare utilization: A systematic review.
    Kwan P; Palmini A
    Epilepsy Behav; 2017 Aug; 73():166-172. PubMed ID: 28641169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs.
    Perucca E; Albani F; Capovilla G; Bernardina BD; Michelucci R; Zaccara G
    Epilepsia; 2006; 47 Suppl 5():16-20. PubMed ID: 17239100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.